T-Knife Therapeutics
t-knife.comLocations
San Francisco, CA, USA · Berlin, Germany
industry
Biotechnology · Biotechnology Research
Size
51 - 200 employees
Stage
Series B
founded in
2018
T-Knife is a developer of T cell receptors intended for T cell therapy of cancer. The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.
Something looks off?Open jobs at T-Knife Therapeutics
On-site & Remote
Seniority
Salary